fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Memantine HCL

All products: not a benefit

Act Memantine · DIN 02324067 · 10 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked November 18, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Act Memantine · DIN 02324067 Manufacturer: Teva Canada Limited; listing date 2010-06-14 Health Canada: Marketed since 2020-04-06 · brand ACT MEMANTINE · ATC N06DX01 MEMANTINE · form Tablet · route Oral · ingredients MEMANTINE HYDROCHLORIDE 10 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02324067)

Source record
DIN 02324067: Act Memantine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 289200037; group id 540; item number 1458; lccId None; manufacturer id TEV Source form: Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.6357; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02324067 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80955
Interchangeable products
Apo-Memantine · DIN 02366487 · not recorded Ebixa · DIN 02260638 · not recorded Jamp-Memantine · DIN 02409895 · not recorded Memantine · DIN 02443082 · not recorded Memantine · DIN 02446049 · not recorded Mint-Memantine · DIN 02531887 · not recorded PMS-Memantine · DIN 02321130 · not recorded Ran-Memantine · DIN 02421364 · not recorded Ratio-Memantine · DIN 02320908 · not recorded Sandoz Memantine FCT · DIN 02375532 · not recorded
Shortage status: resolved shortage (ended November 12, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02324067
Shortage record checked October 6, 2026

Apo-Memantine · DIN 02366487 · 10 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Apo-Memantine · DIN 02366487 Manufacturer: Apotex Inc.; listing date 2011-12-15 Health Canada: Marketed since 2020-05-25 · brand APO-MEMANTINE · ATC N06DX01 MEMANTINE · form Tablet · route Oral · ingredients MEMANTINE HYDROCHLORIDE 10 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02366487)

Source record
DIN 02366487: Apo-Memantine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 289200037; group id 540; item number 1458; lccId None; manufacturer id APX Source form: Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.6357; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02366487 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85130
Interchangeable products
Act Memantine · DIN 02324067 · not recorded Ebixa · DIN 02260638 · not recorded Jamp-Memantine · DIN 02409895 · not recorded Memantine · DIN 02443082 · not recorded Memantine · DIN 02446049 · not recorded Mint-Memantine · DIN 02531887 · not recorded PMS-Memantine · DIN 02321130 · not recorded Ran-Memantine · DIN 02421364 · not recorded Ratio-Memantine · DIN 02320908 · not recorded Sandoz Memantine FCT · DIN 02375532 · not recorded
Shortage status: resolved shortage (ended October 13, 2022); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02366487
Shortage record checked October 6, 2026

Jamp-Memantine · DIN 02409895 · 10 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Jamp-Memantine · DIN 02409895 Manufacturer: Jamp Pharma Corporation; listing date 2015-05-28 Health Canada: Marketed since 2026-09-08 · brand JAMP-MEMANTINE · ATC N06DX01 MEMANTINE · form Tablet · route Oral · ingredients MEMANTINE HYDROCHLORIDE 10 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02409895)

Source record
DIN 02409895: Jamp-Memantine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 289200037; group id 540; item number 1458; lccId None; manufacturer id JPC Source form: Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.6357; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02409895 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89455
Interchangeable products
Act Memantine · DIN 02324067 · not recorded Apo-Memantine · DIN 02366487 · not recorded Ebixa · DIN 02260638 · not recorded Memantine · DIN 02443082 · not recorded Memantine · DIN 02446049 · not recorded Mint-Memantine · DIN 02531887 · not recorded PMS-Memantine · DIN 02321130 · not recorded Ran-Memantine · DIN 02421364 · not recorded Ratio-Memantine · DIN 02320908 · not recorded Sandoz Memantine FCT · DIN 02375532 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02409895
Shortage record checked October 6, 2026

Memantine · DIN 02443082 · 10 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked November 18, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Memantine · DIN 02443082 Manufacturer: Sanis Health Inc.; listing date 2020-06-30 Health Canada: Marketed since 2017-06-14 · brand MEMANTINE · ATC N06DX01 MEMANTINE · form Tablet · route Oral · ingredients MEMANTINE HYDROCHLORIDE 10 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02443082)

Source record
DIN 02443082: Memantine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 289200037; group id 540; item number 1458; lccId None; manufacturer id SAI Source form: Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.6357; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02443082 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92762
Interchangeable products
Act Memantine · DIN 02324067 · not recorded Apo-Memantine · DIN 02366487 · not recorded Ebixa · DIN 02260638 · not recorded Jamp-Memantine · DIN 02409895 · not recorded Memantine · DIN 02446049 · not recorded Mint-Memantine · DIN 02531887 · not recorded PMS-Memantine · DIN 02321130 · not recorded Ran-Memantine · DIN 02421364 · not recorded Ratio-Memantine · DIN 02320908 · not recorded Sandoz Memantine FCT · DIN 02375532 · not recorded
Shortage status: anticipated shortage (last updated May 25, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02443082
Shortage record checked October 6, 2026

Memantine · DIN 02446049 · 10 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Memantine · DIN 02446049 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-06-30 Health Canada: Marketed since 2018-06-08 · brand MEMANTINE · ATC N06DX01 MEMANTINE · form Tablet · route Oral · ingredients MEMANTINE HYDROCHLORIDE 10 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02446049)

Source record
DIN 02446049: Memantine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 289200037; group id 540; item number 1458; lccId None; manufacturer id SIV Source form: Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.6357; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02446049 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93131
Interchangeable products
Act Memantine · DIN 02324067 · not recorded Apo-Memantine · DIN 02366487 · not recorded Ebixa · DIN 02260638 · not recorded Jamp-Memantine · DIN 02409895 · not recorded Memantine · DIN 02443082 · not recorded Mint-Memantine · DIN 02531887 · not recorded PMS-Memantine · DIN 02321130 · not recorded Ran-Memantine · DIN 02421364 · not recorded Ratio-Memantine · DIN 02320908 · not recorded Sandoz Memantine FCT · DIN 02375532 · not recorded
Shortage status: resolved shortage (ended March 1, 2021); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02446049
Shortage record checked October 6, 2026

PMS-Memantine · DIN 02321130 · 10 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked November 18, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
PMS-Memantine · DIN 02321130 Manufacturer: Pharmascience Inc.; listing date 2010-01-05 Health Canada: Marketed since 2009-11-04 · brand PMS-MEMANTINE · ATC N06DX01 MEMANTINE · form Tablet · route Oral · ingredients MEMANTINE HYDROCHLORIDE 10 MG · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02321130)

Source record
DIN 02321130: PMS-Memantine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 289200037; group id 540; item number 1458; lccId None; manufacturer id PMS Source form: Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.6357; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02321130 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80653
Interchangeable products
Act Memantine · DIN 02324067 · not recorded Apo-Memantine · DIN 02366487 · not recorded Ebixa · DIN 02260638 · not recorded Jamp-Memantine · DIN 02409895 · not recorded Memantine · DIN 02443082 · not recorded Memantine · DIN 02446049 · not recorded Mint-Memantine · DIN 02531887 · not recorded Ran-Memantine · DIN 02421364 · not recorded Ratio-Memantine · DIN 02320908 · not recorded Sandoz Memantine FCT · DIN 02375532 · not recorded
Shortage status: resolved shortage (ended December 20, 2019); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02321130
Shortage record checked October 6, 2026

Sandoz Memantine FCT · DIN 02375532 · 10 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Sandoz Memantine FCT · DIN 02375532 Manufacturer: Sandoz Canada Inc.; listing date 2015-02-26 Health Canada: Marketed since 2014-07-17 · brand SANDOZ MEMANTINE FCT · ATC N06DX01 MEMANTINE · form Tablet · route Oral · ingredients MEMANTINE HYDROCHLORIDE 10 MG · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02375532)

Source record
DIN 02375532: Sandoz Memantine FCT Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 289200037; group id 540; item number 1458; lccId None; manufacturer id SDZ Source form: Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.6357; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02375532 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86095
Interchangeable products
Act Memantine · DIN 02324067 · not recorded Apo-Memantine · DIN 02366487 · not recorded Ebixa · DIN 02260638 · not recorded Jamp-Memantine · DIN 02409895 · not recorded Memantine · DIN 02443082 · not recorded Memantine · DIN 02446049 · not recorded Mint-Memantine · DIN 02531887 · not recorded PMS-Memantine · DIN 02321130 · not recorded Ran-Memantine · DIN 02421364 · not recorded Ratio-Memantine · DIN 02320908 · not recorded
Shortage status: active shortage (reported June 15, 2026, last updated July 7, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02375532
Shortage record checked October 6, 2026

Ebixa · DIN 02260638 · 10 mg · tablet

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2026-07-23 — choose a marketed DIN from the same-category list.Discontinued July 23, 2026 · checked November 18, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2026-07-23 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2026-07-23 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Ebixa · DIN 02260638 Manufacturer: Lundbeck Canada Inc.; listing date 2010-01-05 Health Canada: Cancelled post market since 2026-07-23 · brand EBIXA · ATC N06DX01 MEMANTINE · form Tablet · route Oral · ingredients MEMANTINE HYDROCHLORIDE 10 MG · company Lundbeck canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Ebixa: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02260638)

Source record
DIN 02260638: Ebixa Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 289200037; group id 540; item number 1458; lccId None; manufacturer id VLH Source form: Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02260638 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74607
Interchangeable products
Act Memantine · DIN 02324067 · not recorded Apo-Memantine · DIN 02366487 · not recorded Jamp-Memantine · DIN 02409895 · not recorded Memantine · DIN 02443082 · not recorded Memantine · DIN 02446049 · not recorded Mint-Memantine · DIN 02531887 · not recorded PMS-Memantine · DIN 02321130 · not recorded Ran-Memantine · DIN 02421364 · not recorded Ratio-Memantine · DIN 02320908 · not recorded Sandoz Memantine FCT · DIN 02375532 · not recorded
Shortage status: To be discontinued; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02260638
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since July 23, 2026 — choose a marketed DIN from the same-category list.

Mint-Memantine · DIN 02531887 · 10 mg · tablet

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2026-11-04 — choose a marketed DIN from the same-category list.Discontinued November 4, 2026 · checked November 18, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2026-11-04 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2026-11-04 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Mint-Memantine · DIN 02531887 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2024-12-30 Health Canada: Cancelled post market since 2026-11-04 · brand MINT-MEMANTINE · ATC N06DX01 MEMANTINE · form Tablet · route Oral · ingredients MEMANTINE HYDROCHLORIDE 10 MG · company Mint pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada); extract: Marketed February 11, 2025; live record preferred: Cancelled Post Market November 4, 2026 (checked November 18, 2026) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02531887)

Source record
DIN 02531887: Mint-Memantine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 289200037; group id 540; item number 1458; lccId None; manufacturer id MIN Source form: Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.6357; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02531887 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada); extract: Marketed February 11, 2025; live record preferred: Cancelled Post Market November 4, 2026 (checked November 18, 2026) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102097
Interchangeable products
Act Memantine · DIN 02324067 · not recorded Apo-Memantine · DIN 02366487 · not recorded Ebixa · DIN 02260638 · not recorded Jamp-Memantine · DIN 02409895 · not recorded Memantine · DIN 02443082 · not recorded Memantine · DIN 02446049 · not recorded PMS-Memantine · DIN 02321130 · not recorded Ran-Memantine · DIN 02421364 · not recorded Ratio-Memantine · DIN 02320908 · not recorded Sandoz Memantine FCT · DIN 02375532 · not recorded
Shortage status: anticipated shortage (last updated July 28, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02531887
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since November 4, 2026 — choose a marketed DIN from the same-category list.

Ran-Memantine · DIN 02421364 · 10 mg · tablet

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2025-07-10 — choose a marketed DIN from the same-category list.Discontinued July 10, 2025 · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2025-07-10 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2025-07-10 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Ran-Memantine · DIN 02421364 Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2014-09-25 Health Canada: Cancelled post market since 2025-07-10 · brand RAN-MEMANTINE · ATC N06DX01 MEMANTINE · form Tablet · route Oral · ingredients MEMANTINE HYDROCHLORIDE 10 MG · company Ranbaxy pharmaceuticals canada inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02421364)

Source record
DIN 02421364: Ran-Memantine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 289200037; group id 540; item number 1458; lccId None; manufacturer id RAN Source form: Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.6357; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02421364 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90599
Interchangeable products
Act Memantine · DIN 02324067 · not recorded Apo-Memantine · DIN 02366487 · not recorded Ebixa · DIN 02260638 · not recorded Jamp-Memantine · DIN 02409895 · not recorded Memantine · DIN 02443082 · not recorded Memantine · DIN 02446049 · not recorded Mint-Memantine · DIN 02531887 · not recorded PMS-Memantine · DIN 02321130 · not recorded Ratio-Memantine · DIN 02320908 · not recorded Sandoz Memantine FCT · DIN 02375532 · not recorded
Shortage status: discontinued (July 12, 2017, reported by RANBAXY PHARMACEUTICALS CANADA INC.); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02421364
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since July 10, 2025 — choose a marketed DIN from the same-category list.

Ratio-Memantine · DIN 02320908 · 10 mg · tablet

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2018-06-19 — choose a marketed DIN from the same-category list.Discontinued June 19, 2018 · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2018-06-19 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2018-06-19 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Ratio-Memantine · DIN 02320908 Manufacturer: Ratiopharm Inc.; listing date 2010-01-05 Health Canada: Cancelled post market since 2018-06-19 · brand RATIO-MEMANTINE · ATC N06DX01 MEMANTINE · form Tablet · route Oral · ingredients MEMANTINE HYDROCHLORIDE 10 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02320908)

Source record
DIN 02320908: Ratio-Memantine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 289200037; group id 540; item number 1458; lccId None; manufacturer id RPH Source form: Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.6357; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02320908 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80632
Interchangeable products
Act Memantine · DIN 02324067 · not recorded Apo-Memantine · DIN 02366487 · not recorded Ebixa · DIN 02260638 · not recorded Jamp-Memantine · DIN 02409895 · not recorded Memantine · DIN 02443082 · not recorded Memantine · DIN 02446049 · not recorded Mint-Memantine · DIN 02531887 · not recorded PMS-Memantine · DIN 02321130 · not recorded Ran-Memantine · DIN 02421364 · not recorded Sandoz Memantine FCT · DIN 02375532 · not recorded
Shortage status: discontinued (January 31, 2018, reported by TEVA CANADA LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02320908
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since June 19, 2018 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (28:92 Miscellaneous Central Nervous System Drugs) and how they are covered

Matched class: 28:92 Miscellaneous Central Nervous System Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: PIZOTYLINE Some products covered without a code (check the product listing): ATOMOXETINE HCL, PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE 28:92 Miscellaneous Central Nervous System Drugs

ATOMOXETINE HCL

· 59 products · Listed, not a benefit (5), General benefit (40), Off-Formulary Interchangeable, not an ODB benefit (14) · strengths: 10mg, 18mg, 25mg, 40mg, 60mg, 80mg, 100mg · Cap

PIZOTYLINE

· 1 products · General benefit · strengths: 1mg · Tab

PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE

· 28 products · General benefit (19), Off-Formulary Interchangeable, not an ODB benefit (7), Listed, not a benefit (2) · strengths: 0.25mg, 0.5mg, 1mg, 1.5mg · Tab

ACAMPROSATE CALCIUM

· 1 products · Limited Use, codes 531 · strengths: 333mg · DR Tab

ENTACAPONE

· 4 products · Limited Use, codes 367 · strengths: 200mg · Tab

ALMOTRIPTAN

· 9 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 6.25mg, 12.5mg · Tab

DIMETHYL FUMARATE

· 18 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 120mg, 240mg · DR Cap

ELETRIPTAN

· 16 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 20mg, 40mg · Tab

FROVATRIPTAN SUCCINATE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2.5mg · Tab

NARATRIPTAN HYDROCHLORIDE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1mg, 2.5mg · Tab

RIZATRIPTAN

· 44 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 5mg, 10mg · Orally Disintegrating Tab, Tab

SUMATRIPTAN SUCCINATE

· 38 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 6mg/0.5mL, 25mg, 50mg, 100mg · Inj Sol-Pref Syr 0.5mL Pk, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 28:92 and 1 more
Full class listing Related classes: 28:08 Analgesics, 28:10 Opiate Antagonists, 28:12 Anticonvulsants, 28:16 Psychotherapeutic Agents, 28:20 C.N.S. Stimulants, 28:24 Sedatives and Hypnotics, 28:36 Antiparkinsonian Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATION AND CLINICAL USE pms-MEMANTINE (memantine hydrochloride) may be useful as monotherapy or as adjunctive therapy with cholinesterase inhibitors1 for the symptomatic treatment of patients with moderate to severe dementia of the Alzheimer’s type. pms-MEMANTINE tablets should only be prescribed by (or following consultation with) clinicians who are experienced in the diagnosis and management of Alzheimer’s disease. In a 28-week placebo controlled monotherapy trial, patients with moderate to severe Alzheimer’s disease showed stabilization or less worsening of functional and cognitive symptoms and of global assessment when treated with memantine hydrochloride compared to placebo. In a 24 week “add-on” placebo controlled trial in which patients were treated with either memantine hydrochloride or placebo as add-on to ongoing donepezil therapy, stabilization or less worsening of functional and cognitive symptoms and of global assessment was observed in patients with moderate to severe Alzheimer’s disease when treated with memantine hydrochloride compared to placebo. 1 Cholinesterase inhibitors refers to only those which are approved in Canada … https://pdf.hres.ca/dpd_pm/00034930.PDF PM date: May 10, 2016 Source product: PMS-MEMANTINE; DIN 02321130; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Sandoz Memantine FCT · DIN 02375532 Shortage status: active shortage (reported 2026-06-15, last updated 2026-07-07); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02375532

Check this DIN again

Ebixa · DIN 02260638 Shortage status: To be discontinued; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02260638

Check this DIN again

Ran-Memantine · DIN 02421364 Shortage status: discontinued (2017-07-12, reported by RANBAXY PHARMACEUTICALS CANADA INC.); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02421364

Check this DIN again

Ratio-Memantine · DIN 02320908 Shortage status: discontinued (2018-01-31, reported by TEVA CANADA LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02320908

Check this DIN again

Other review policies

For Act Memantine, Apo-Memantine, Jamp-Memantine, Memantine, PMS-Memantine, Sandoz Memantine FCT, Ebixa, Mint-Memantine, Ran-Memantine, Ratio-Memantine: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026